logo

For the Inventor, By the Inventor

Redwood City, CA, United States of America

Abbvie Biotherapeutics Inc.

USPTO Granted Patents = 52

% Expired Patents = 38.5



Forward Citations = 275

Loading Chart...
Loading Chart...

51 inventors (with patents filed for the assignee):

goldMedal J Yun Tso (10 out of 49 patents)

silverMedal Yoshiko Akamatsu (10 out of 10 patents)

bronzeMedal David Powers (10 out of 29 patents)

4.  Fiona A Harding (10 out of 26 patents)

5.  Robert B Dubridge (9 out of 49 patents)

6.  Kurt C Gish (7 out of 27 patents)

7.  Shiming Ye (6 out of 6 patents)

8.  Marna Williams (6 out of 11 patents)

9.  Nicholas F Landolfi (6 out of 19 patents)

10.  Gao Liu (6 out of 13 patents)

11.  James W Purcell (5 out of 5 patents)

12.  Diane Sau Mun Cohen (5 out of 5 patents)

13.  Diane Hollenbaugh (5 out of 20 patents)

14.  Ping Y Huang (5 out of 6 patents)

15.  Veronica Juan (4 out of 15 patents)


Core Competencies:
Anti-CD19
Anti-CS1
Anti-VEGF
Antibody Drug Conjugates
Bispecific Binding Proteins
Fc Variants
CTLA4 Proteins
Anti-PD-1
Anti-huLRRC15
Anti-TNF-alpha
Nucleic Acid Molecules
Pharmaceutical Formulations

52 patents:

1. 12478689 - ANTI-CD19 ANTIBODY DRUG CONJUGATES (2025-11-25),
2. 12121589 - Anti-CD19 antibody drug conjugates (2024-10-22),
3. 11045480 - Anti-huLRRC15 antibody drug conjugates and methods for their use (2021-06-29),
4. 10875921 - Anti-4-1BB antibodies and their uses (2020-12-29),
5. 10844131 - Anti-CD40 antibody (2020-11-24),
6. 10730953 - Anti-PD-1 antibodies and their uses (2020-08-04),
7. 10604584 - Anti-OX40 antibodies and their uses (2020-03-31),
8. 10603389 - Anti-cMet antibody drug conjugates and methods for their use (2020-03-31),
9. 10597460 - Anti-CD40 antibodies (2020-03-24),
10. 10556962 - Anti-OX40 antibodies and their uses (2020-02-11),
11. 10519243 - Anti-CD40 antibodies (2019-12-31),
12. 10442859 - Therapeutic use of anti-CS1 antibodies (2019-10-15),
13. 10400041 - Nucleic acid molecules encoding anti-CD40 antibodies (2019-09-03),
14. 10383948 - Anti-cMet antibody drug conjugates and methods for their use (2019-08-20),
15. 10308713 - Anti-CS1 antibodies and antibody drug conjugates (2019-06-04),
Company Overview
Abbvie Biotherapeutics Inc., based in Redwood City, CA, specializes in the development of innovative therapies utilizing antibody drug conjugates. The company focuses on advanced therapeutic modalities, including anti-CD19, anti-CS1, and anti-VEGF technologies, aimed at treating various cancers and autoimmune diseases. Their research encompasses bispecific binding proteins, Fc variants, and CTLA4 proteins, as well as anti-PD-1 approaches, positioning them at the forefront of biotherapeutic advancements.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Abbvie Biotherapeutics Inc. USPTO Patent Assignee Logo
52 Patents

#45 in Redwood City, CA

#1,589 in California

#6,769 in US

#13,571 in the World

Redwood City, CA (US)
Redwood City, CA, United States of America

Abbvie Biotherapeutics Inc.

Forward Citations = 275

51 inventors:

goldMedal J Yun Tso (10 out of 49 patents)

silverMedal Yoshiko Akamatsu (10 out of 10 patents)

bronzeMedal David Powers (10 out of 29 patents)

4.  Fiona A Harding (10 out of 26 patents)

5.  Robert B Dubridge (9 out of 49 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Abbvie Biotherapeutics Inc.. Retrieved from https://idiyas.com/company/abbvie-biotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…